790 research outputs found
Babel, or the local distortion of the Greek language
No full textTitle: Βαβυλωνία ἤ ἡ κατά τόπους διαφθορά τῆς ἑλληνικῆς γλώσσας. Κωµωδία (Babel, or the local distortion of the Greek language: A comedy) Originally published: Ναύπλιο (Nafplio), Τυπογραφεῖsο Κωνσταντίνου Τόµπρα ἐκ Κυδωνιῶν καὶ Κωνσταντίνου Ἰωαννίδη ἐκ Σµύρνης, 1836 Language: Greek The excerpt used is from D. C. Vyzantios, Βαβυλωνία, introduction by Spyros Evangelatos (Athens: Εστία, 1993), pp.1–3. About the author Dimitrios Vyzantios (pseudonym of Dimitrios K. Hatziaslanis) [1790, Constantin..
Dimitrios Tsamis Karatasos : a symbol of Greek, Serbian and Bulgarian friendship
No full textTwo Serbian texts extol the contribution of Dimitrios Tsamis Karatasos to the Balkan joint effort to throw off the Ottoman yoke. These texts are analysed by the author within the historical framework of their period, so that the man’s personality and work may be accurately evaluated from a fresh viewpoint. More specifically, the author conducts a research on the tombstone of Dimitrios Tsamis Karatasos, which he discovered himself at Naoussa, and the octet engraved on it, which is also published here. The work is illustrated by seven plates, of which four have not been published previously
The Remains of authoritarianism : bureaucracy and civil society in post-authoritarian Greece
No full textDimitrios A. Sotiropoulos. 30 cm. He presented this paper at a seminar held at the Center on October 21, 1994. - T.p. Includes bibliographical references (p. 31-35
Erratum: Korkovelos, A., et al. The role of open access data in geospatial electrification planning and the achievement of SDG7. An OnSSET-based case study for Malawi. <i>Energies</i> 2019, 12(7), 1395
No full textThe authors wish to make a change in author names (adding new author—Dimitrios Mentis) to this paper
Cross over trials: empirical meta - analytic evaluation
No full textRandomized parallel arm design trials constitute the majority of the trials analyzed in meta-analyses. Το a lesser extent randomized crossover trials are also used. Cross over trials don’t have an accepted and well-established method for their meta-analysis. We tried to evaluate empirically how cross over trial results were analyzed in meta-analyses and if their results agreed with those of parallel arm trials in the same question. We studied 26 systematic reviews with 28 meta-analyses. Each meta-analysis had at least one cross over study. The initial sample had 334 systematic reviews retrieved by Cochrane Library Issue 2. 2003. 12 out of the 28 meta-analyses did not mention at all their approach towards cross over trials’ results, 9 used only the first period results, 3 combined results from the first and second period, 1 used only data from the second period and 3 did not have consistent approach for the analysis of cross over data. The 28 meta-analyses had 137 crossover trials with 7162 patients and 132 parallel arm trials with 11398 patients. Effect sizes correlated with the two types of design (ρ =0.72). The summary relative odd ratio for parallel arms versus cross over studies for favorable outcomes was 0.87 (95% CI, 0.74-1.02). Cross over designs contribute evidence in a fifth of systematic reviews, but few meta-analyses made use of their data. The results of cross over trials tended to agree with those of parallel arms trials, although there was a trend for more conservative treatment effect estimates in parallel arm trials. Cross over trials are not as popular as parallel arm trials. Nevertheless, one of their major indications is the trials of clinical pharmacology. Pharmaceutical industries sponsor the majority of randomized clinical trials. One can easily question if pharmaceutical industries can influence the choice of comparators of the trials that are sponsoring.85 We tried to assess how often major pharmaceutical companies sponsor trials that evaluate their products and how often they sponsor trials where their products are directly compared to licensed products of other major companies. We used randomized trials and we focused on cross over trials specifically. We studied 577 randomized trials that were sponsored by 15 major companies and were registered on ClinicalTrials.gov on 2006. 82% of them had a single industry sponsor. The compared intervention belonged to a single company in 67% of the trials. All 15 companies preferred to be unique industry sponsor and unique owner of the evaluated interventions. Co-sponsoring usually reflected co-ownership or common financial interests. Head to head comparisons of different active interventions that belonged to different companies were found only in 18 studies with more than two industry sponsors. Our findings did not change when we focused on cross- over trials. Cross over trials were 12.6% (73/577) of the randomized trials sample and were sponsored by 12 companies. 90% of cross over trials was sponsored by only one pharmaceutical industry. The interventions belonged to a single company in 86% of these trials. More than two sponsors were observed in 8 trials, but head to head comparisons among intervention owned by the sponsoring companies were not found. We can easily conclude that head to head comparisons were rarely observed in trials sponsored by pharmaceutical industries and were not observed at all in cross over trials. It seems that each company has a clinical research agenda not only focused on its own products but also aiming to avoid comparisons with products of other companies. This diminishes the ability to understand the merits of different interventions for the same condition.Η πλειοψηφία των μελετών που χρησιμοποιούνται στις μετα-αναλύσεις είναι τυχαιοποιημένες δοκιμές παράλληλων ομάδων. Υπάρχει όμως και μια άλλη κατηγορία τυχαιοποιημένων μελετών που είναι οι μελέτες διασταυρούμενης μετάβασης. Για τις μελέτες αυτές που παρουσιάζουν ιδιαιτερότητες, τόσο μεθοδολογικές όσο και στατιστικής ανάλυσης, δεν υπάρχει καθιερωμένη μέθοδος ανάλυσης δεδομένων στα πλαίσια των μετα-αναλύσεων. Στην παρούσα διδακτορική διατριβή προσπαθήσαμε να αξιολογήσουμε εμπειρικά τον τρόπο που αναλύονται τα δεδομένα των μελετών διασταυρούμενης μετάβασης στις μετα-αναλύσεις, καθώς και να διαπιστώσουμε αν τα αποτελέσματα των μελετών αυτών συμφωνούν με εκείνα των μελετών παραλλήλων ομάδων. Μελετήσαμε δείγμα 26 συστηματικών ανασκοπήσεων που περιλάμβανε 28 ανεξάρτητες μετα-αναλύσεις, με τουλάχιστον μια μελέτη διασταυρούμενης μετάβασης. Το δείγμα αυτό προέκυψε από ένα αρχικό δείγμα 334 ανασκοπήσεων της Cochrane Library Issue 2, 2003. Από τις 28 μετα-αναλύσεις, οι 12 δεν ανέφεραν καθόλου την προσέγγιση που ακολούθησαν στην ανάλυση των αποτελεσμάτων, οι 9 χρησιμοποίησαν μόνο δεδομένα της πρώτης περιόδου, οι 3 συνδύασαν δεδομένα της πρώτης και της δεύτερης περιόδου, 1 χρησιμοποίησε δεδομένα της δεύτερης περιόδου και 3 χρησιμοποίησαν διαφορετικές προσεγγίσεις στην ίδια μετα-ανάλυση. Επιπλέον, από τις 28 μετα-αναλύσεις προέκυψαν 137 μελέτες διασταυρούμενης μετάβασης με 7.162 ασθενείς και 132 μελέτες παράλληλων ομάδων με 11.398 ασθενείς. Τα μεγέθη αποτελέσματος (effect sizes) συσχετίζονταν πολύ καλά ανάμεσα στα δυο διαφορετικού σχεδιασμού είδη μελετών (ρ =0.72). Ο συνοπτικός σχετικός λόγος αναλογιών (relative odd ratio) μεταξύ των μελετών παράλληλων ομάδων και των μελετών διασταυρούμενης μετάβασης για ευνοϊκές εκβάσεις ήταν 0.87 (95% CI, 0.74-1.02). Οι μελέτες διασταυρούμενης μετάβασης συνεισφέρουν δεδομένα περίπου στο ένα πέμπτο των συστηματικών ανασκοπήσεων, ελάχιστες, όμως, μετα-αναλύσεις αξιοποιούν πλήρως όλα τα δεδομένα τους. Τα αποτελέσματα των μελετών διασταυρούμενης μετάβασης συμφωνούν με εκείνα των παράλληλων ομάδων, αν 82 και καταγράφηκε μια μικρή τάση για πιο συντηρητικά θεραπευτικά αποτελέσματα στις μελέτες παράλληλων ομάδων. Οι μελέτες διασταυρούμενης μετάβασης δεν είναι ιδιαίτερα δημοφιλείς μελέτες. Θεωρούνται, όμως, μελέτες με απόλυτη ένδειξη για ερευνητικά προγράμματα κλινικής φαρμακολογίας. Είναι επίσης γνωστό, ότι η σύγχρονη φαρμακευτική βιομηχανία επιχορηγεί την πλειοψηφία των τυχαιοποιημένων μελετών και αυτό εγείρει σημαντικά ερωτήματα σχετικά με την επιρροή των βιομηχανιών-χορηγών στην επιλογή των συγκρινόμενων προϊόντων. Προσπαθήσαμε, λοιπόν, ταυτόχρονα, να καταγράψουμε πόσο συχνά οι φαρμακευτικές εταιρείες επιχορηγούν κλινικές δοκιμές που αξιολογούν δικά τους προϊόντα, τόσο στο σύνολο των τυχαιοποιημένων δοκιμών, όσο και ειδικότερα στις μελέτες διασταυρούμενης μετάβασης, καθώς και πόσο συχνά επιχορηγούν μελέτες στις οποίες τα προϊόντα τους συγκρίνονται απ’ ευθείας με εκείνα άλλων φαρμακευτικών εταιρειών. Μελετήσαμε 577 τυχαιοποιημένες μελέτες που επιχορηγήθηκαν από 15 μεγάλες εταιρείες και ήταν καταγεγραμμένες στο CliniclTrials.gov to 2006. To 82% των μελετών είχε μόνο ένα βιομηχανικό χορηγό. Τα συγκρινόμενα θεραπευτικά σχήματα-παρεμβάσεις ανήκαν σε μια μόνο βιομηχανία στο 67% των μελετών. Και οι 15 εταιρείες προτιμούσαν να είναι μοναδικοί χορηγοί ή και μοναδικοί ιδιοκτήτες των συγκρινόμενων παρεμβάσεων. Όταν καταγράφονταν δυο ή περισσότεροι χορηγοί, συνήθως επρόκειτο για συνιδιοκτησία της ή των παρεμβάσεων ή για κοινά εμπορικά συμφέροντα. Απευθείας συγκρίσεις μεταξύ ενεργών θεραπευτικών παρεμβάσεων που ανήκαν σε διαφορετικές εταιρείες διαπιστώθηκαν μόνο σε 18 μελέτες με περισσότερους από δύο βιομηχανικούς χορηγούς
The Exemplary Life of Dimitrios Vikelas (1835-1908)
No full textThis paper describes the "satisfying curve" of Dimitrios Vikelas' life journey, starting from Syros in 1835, moving via Constantinople, Odessa, and Syros again, to London, Paris and finally Athens. It explores Vikelas' multiple aspects, as merchant, writer, traveller, lecturer and essayist, Olympic founder, educationalist, book collector and philanthropist, all of which were united in the public-spirited man of letters (logios). It sets Vikelas in the context of the Greek commercial diaspora, the world of the London expatriate Greek community, and the dynamic society of late nineteenth-century Athens, beginning in the 1870s to act as a magnet to Greek expatriates. The author stresses two qualities of Vikelas: his belief in the idea of a progressive Greek state marked by advances in education, culture, tourism and standards of public life; and the self-awareness and experience which inform his autobiographical writings, not only his memoir My Life but also his last such work, The War of 1897
Turbulence structure and flow resistance in oscillatory boundary layer flows
No full textSubmission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2022-12-01The student, Dimitrios Fytanidis, accepted the attached license on 2020-12-01 at 15:14.The student, Dimitrios Fytanidis, submitted this Dissertation for approval on 2020-12-01 at 15:22.This Dissertation was approved for publication on 2020-12-03 at 08:17.DSpace SAF Submission Ingestion Package generated from Vireo submission #16014 on 2021-03-04 at 16:32:49Made available in DSpace on 2021-03-05T21:45:43Z (GMT). No. of bitstreams: 15
FYTANIDIS-DISSERTATION-2020.pdf: 35582374 bytes, checksum: 7b9c9c750d2433e542eaf143a5250e52 (MD5)
Chapter 3 video 1.mp4: 224359 bytes, checksum: 6afa84d5c6e82411e07f0511842c0a45 (MD5)
Chapter 3 video 2.mp4: 235936 bytes, checksum: 67eb7a455fb5fabea8be13df717776e4 (MD5)
Chapter 3 video 3.mp4: 229067 bytes, checksum: c935df21c9eafbe725b9242f872ce935 (MD5)
Chapter 3 video 4.mp4: 234118 bytes, checksum: 25f0589bd05aefb66ca37a8bb6328ae9 (MD5)
Chapter 3 video 5.mp4: 236618 bytes, checksum: 9fd9cf1dd3c46235f634db8e78b204f4 (MD5)
Chapter 3 video 6.mp4: 299851 bytes, checksum: b92ed9f2c8fc2eb08fdc3b415a0a01bb (MD5)
Chapter 3 video 7.mp4: 500994 bytes, checksum: 8e483049044150c77b60f4c36d846ada (MD5)
Chapter 3 video 8.mp4: 440636 bytes, checksum: 32f7a6af91937d0494abaeb85b9b693e (MD5)
Chapter 3 video 9.mp4: 405371 bytes, checksum: 4483e992585bad044eb21d13dd64cbad (MD5)
Chapter 4 video 1.mp4: 11721062 bytes, checksum: 16f6a8e700a78c59c9179829882b2b3c (MD5)
Chapter 4 video 2.mp4: 24428028 bytes, checksum: b11b5fcf99ef1f088f0cbd0fd681f914 (MD5)
Chapter 4 video 3.mp4: 61362991 bytes, checksum: 75b033db9ab7d86256113f026636a85a (MD5)
Copyrights.pdf: 1168055 bytes, checksum: 92c97ab45ac524ef66a379b6ba515d32 (MD5)
LICENSE.txt: 4216 bytes, checksum: 8139025cc39d2751fa86c850a031efc3 (MD5)
Previous issue date: 2020-12-03Embargo set by: Seth Robbins for item 117320
Lift date: 2023-03-05T21:45:47Z
Reason: Author requested closed access (OA after 2yrs) in Vireo ETD systemEmbargo set by: Seth Robbins for item 117320
Lift date: 2023-03-05T21:47:41Z
Reason: Author requested closed access (OA after 2yrs) in Vireo ETD systemAuthor requested closed access (OA after 2yrs) in Vireo ETD systemLimite
Correction: The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium (Trials, (2023), 24, 1, (61), 10.1186/s13063-023-07093-7)
No full text\ua9 2023, The Author(s).Following publication of the original article [1], it was noticed that the author name Dimitrios Megaritis was incorrectly written as Dimitrios Magaritis. The author group has been updated above and the original article has been corrected
Implications of vehicle automation for accessibility and social inclusion of people on low income, people with physical and sensory disabilities, and older people
No full textGreen Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.Transport and Logistic
Dimitrios Mavrokordatos Disproving the Hemostatic Myth of Aqua Binelli
No full text“Aqua Binelli” or “Aqua Balsamica Arterialis” was a hemostatic compound invented by the Italian Fedele Binelli in 1797. Its hemostatic properties were viewed as the solution to treating hemorrhage in cases of wounds and surgical operations. Those who opposed the compound were persuaded of its total lack of effectiveness, supporting the view that hemostasis could be achieved by exerting pressure on, stitching, and ligating a vessel. The publications of Karl Ferdinand von Gräfe, Professor at the University of Berlin and fervent advocate of Aqua Binelli, helped spread the use of the compound in Europe. In 1832, however, one of his students, a young Greek named Dimitrios Mavrokordatos, who became the first Professor of Anatomy and Physiology in the newly established University of Athens in 1837, published in Würzburg his dissertation titled Observations on the Potency of Aqua Binelli (Weitere Nachrichten über das Binellische Wasser), where a completely different picture emerged relating to those applications of the compound that von Gräfe considered successful. The case of Mavrokordatos’ dissertation was a typical 19th-century scientific controversy between a young student and his teacher who enjoyed the support of his associates. Eventually, the myth of the hemostatic activity of Aqua Binelli was debunked. © The Author(s) 2020
- …
